Hydrator therapies for cystic fibrosis lung disease

Pediatric Pulmonology

Volumn 43, Issue 9 SUPPL. A, 2008, Pages

  Donaldson, Scott H ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Airway surface liquid; Cystic fibrosis; Therapy

Indexed keywords

AMILORIDE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; CHLORIDE CHANNEL; DENUFOSOL; DORNASE ALFA; DURAMYCIN; EPITHELIAL SODIUM CHANNEL; LONG ACTING DRUG; MANNITOL; PS 552; PURINERGIC P2Y2 RECEPTOR; PURINERGIC RECEPTOR STIMULATING AGENT; SALBUTAMOL; SHORT ACTING DRUG; SODIUM CHLORIDE; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VX 770;

AEROSOL; ANTIBIOTIC THERAPY; BRONCHOSPASM; CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DEHYDRATION; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE TRANSFER; HUMAN; HYDRATION; ION TRANSPORT; MUCOCILIARY CLEARANCE; NONHUMAN; OSMOSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; REVIEW; SURFACE PROPERTY;

EID: 50849135221     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20857     Document Type: Review

References (33)

1. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109:571-577.
2. Matsui H, Grubb B, Tarran R, Randell S, Gatzy J, Davis C, Boucher R. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-1015.
3. Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004;10:487-493.
4. Matsui H, Davis CW, Tarran R, Boucher RC. Osmotic water permeabilities of cultured, well-differentiated normal and cystic fibrosis airway epithelia [see comments]. J Clin Invest 2000;105:1419-1427.
5. Tarran R, Trout L, Donaldson SH, Boucher RC. Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia. J Gen Physiol 2006;127:591-604.
6. Tarran R, Button B, Picher M, Paradiso AM, Ribeiro CM, Lazarowski ER, Zhang L, Collins PL, Pickles RJ, Fredburg JJ, Boucher RC. Normal and cystic fibrosis airway surface liquid homeostasis: the effects of phasic shear stress and viral infections. J Biol Chem 2005;280:35751-35759.
7. Huang PB, Lazarowski ER, Tarran R, Milgram SL, Boucher RC, Stutts MJ. Compartmentalized autocrine signaling to cystic fibrosis transmembrane conductance regulator at the apical membrane of airway epithelial cells. Proc Natl Acad Sci USA 2001;98:14120-14125.
8. Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Conn JA, Rossier BC, Boucher RC. CFTR as a cAMP-dependent regulator of sodium channels [see comments]. Science 1995;269:847-850.
9. Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bautovich GJ, King M, Bye PT. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997;52:900-903.
10. Eng P, Morton J, Douglass J, Riedler J, Wilson J, Robertson C. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996;21:77-83.
11. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-250.
12. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240.
13. Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med 2006;12:445-452.
14. Robinson M, Daviskas E, Eberl S, Baker J, Chan HK, Anderson SD, Bye PT. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999;14:678-685.
15. Olivier KN, Bennett WD, Hohneker KW, Zeman KL, Edwards LJ, Boucher RC, Knowles MR. Acute safety and effects on mucociliary clearance of aerosolized uridine 5′-triphosphate +/-amiloride in normal human adults. Am J Respir Crit Care Med 1996;154:217-223.
16. Bennett WD, Olivier KN, Zeman KL, Hohneker KW, Boucher RC, Knowles MR. Effect of uridine 5′-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med 1996;153:1796-1801.
17. Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005;39:339-348.
18. Deterding RR, Lavange LM, Engels JM, Mathews DW, Coquillette SJ, Brody AS, Millard SP, Ramsey BW. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007;176:362-369.
19. McNulty MJ, Hutabarat RH, Findlay JW, Devereux K, Knick VC, Harvey RJ, Molina L. Pharmacokinetics and tissue distribution of the nonadecapeptide Moli1901 in rats and mice. Xenobiotica 2003;33:197-210.
20. Zeitlin PL, Boyle MP, Guggino WB, Molina L. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2004;125:143-149.
21. Grasemann H, Stehling F, Brunar H, Widmann R, Laliberte TW, Molina L, Doring G, Ratjen F. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 2007;131:1461-1466.
22. Kohler D, App E, Schmitz-Schumann M, Wurtemberger G, Matthys H. Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibroses. Eur Respir J Dis Suppl 1986;146:319-326.
23. Sood N, Bennett WD, Zeman K, Brown J, Foy C, Boucher RC, Knowles MR. Increasing concentration of inhaled saline with or without amiloride: effect on mucociliary clearance in normal subjects. Am J Respir Crit Care Med 2003;167:158-163.
24. App E, King M, Helfesrieder R, Kohler D, Matthys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis 1990;141:605-612.
25. Graham A, Hasani A, Alton E, Martin G, Marriott C, Hodson M, Clarke S, Geddes D. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993;6:1243-1248.
26. Knowles M, Church N, Waltner W, Yankaskas J, Gilligan P, King M, Edwards L, Helms R, Boucher R. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990;322:1189-1194.
27. Hirsh AJ, Molino BF, Zhang J, Astakhova N, Geiss WB, Sargent BJ, Swenson BD, Usyatinsky A, Wyle MJ, Boucher RC, Smith RT, Zamurs A, Johnson MR. Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J Med Chem 2006;49:4098-4115.
28. Donaldson S, Smith R, Doran J, DiMassimo B, Zeman K, Bennett B, Hurd H, Hopkins S. Safety, Pharmacokinetics and Effects on Mucus Clearance Following Administration of 552-02 to Normal Healthy Volunteers. Pediatr Pulmonol Suppl 2005;28:218.
29. Flotte TR, Ng P, Dylla DE, McCray PB, Jr., Wang G, Kolls JK, Hu J. Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis. Mol Ther 2007;15:229-241.
30. Davis PB, Cooper MJ. Vectors for airway gene delivery. AAPS J 2007;9:E11-E17.
31. Van GF, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, Neuberger T, Olson E, Panchenko V, Rader J, Singh A, Stack JH, Tung R, Grootenhuis PD, Negulescu P. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006;290:L1117-L1130.
32. Elkins MR, Tingpej P, Moriarty CP, Yozghatlian V, Rose BR, Harbour C, Bye PT. Tolerability of hypertonic saline when delivered rapidly via the eFlow rapid nebulizer in subjects with cystic fibrosis. Pediatr Pulmonol 2006;suppl 29:243.
33. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, Thompson S, Bush A, Wallis C. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358:1316-1321.